Oxford Biomedica plc (LON:OXB)
London
· Delayed Price · Currency is GBP · Price in GBX 587.00
-14.00 (-2.33%)
Apr 29, 2026, 8:00 AM GMT
Oxford Biomedica Cash Flow Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -30.13 | -43.19 | -157.49 | -39.16 | 19.01 | Upgrade
|
| Depreciation & Amortization | 17.58 | 20.09 | 21.51 | 20.29 | 12.46 | Upgrade
|
| Other Amortization | 2.27 | 2.34 | 7.2 | 6.66 | - | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.02 | 0.29 | -0.82 | -21.33 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 0.18 | 99.29 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | - | 0.05 | 0.17 | Upgrade
|
| Stock-Based Compensation | 4.68 | 1.69 | 3.52 | 6.47 | 3.98 | Upgrade
|
| Other Operating Activities | 2.86 | 2.32 | -19.17 | 9.5 | 2.75 | Upgrade
|
| Change in Accounts Receivable | -21.66 | -33.34 | 28.79 | -17.88 | 6.89 | Upgrade
|
| Change in Inventory | -1.85 | 2.19 | -0.25 | 0.67 | -2.61 | Upgrade
|
| Change in Accounts Payable | 8.72 | 2.89 | -18.13 | 16.96 | -0.66 | Upgrade
|
| Change in Unearned Revenue | 18.18 | -6.05 | 7.03 | 5.16 | -16.53 | Upgrade
|
| Change in Other Net Operating Assets | -0.16 | -0.08 | 0 | - | - | Upgrade
|
| Operating Cash Flow | 0.51 | -50.67 | -28.52 | -12.62 | 25.46 | Upgrade
|
| Operating Cash Flow Growth | - | - | - | - | 716.91% | Upgrade
|
| Capital Expenditures | -4.76 | -7.5 | -9.83 | -16.3 | -9.46 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | 8.39 | 60 | - | Upgrade
|
| Cash Acquisitions | -3.34 | 9 | - | -99.21 | - | Upgrade
|
| Other Investing Activities | 2.38 | 4.12 | 4.25 | -0.96 | - | Upgrade
|
| Investing Cash Flow | -5.72 | 5.63 | 2.81 | -56.46 | -9.46 | Upgrade
|
| Long-Term Debt Issued | 41.95 | - | - | 64.87 | - | Upgrade
|
| Long-Term Debt Repaid | -42.84 | -5.19 | -3.12 | -32.54 | -4.52 | Upgrade
|
| Net Debt Issued (Repaid) | -0.88 | -5.19 | -3.12 | 32.32 | -4.52 | Upgrade
|
| Issuance of Common Stock | 58.06 | 17.53 | 0.65 | 80.15 | 51.6 | Upgrade
|
| Other Financing Activities | -14.91 | -9.43 | -10.24 | -13.85 | -0.87 | Upgrade
|
| Financing Cash Flow | 42.26 | 2.91 | -12.7 | 98.62 | 46.21 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.81 | -0.94 | 0.85 | 2.8 | - | Upgrade
|
| Net Cash Flow | 36.23 | -43.07 | -37.57 | 32.34 | 62.2 | Upgrade
|
| Free Cash Flow | -4.25 | -58.16 | -38.35 | -28.91 | 15.99 | Upgrade
|
| Free Cash Flow Margin | -2.52% | -45.16% | -42.83% | -20.65% | 11.20% | Upgrade
|
| Free Cash Flow Per Share | -0.04 | -0.56 | -0.40 | -0.30 | 0.19 | Upgrade
|
| Cash Interest Paid | 12.92 | 9.43 | 10.24 | 7.68 | 0.87 | Upgrade
|
| Cash Income Tax Paid | -5.13 | - | -7.51 | -0.56 | -0.99 | Upgrade
|
| Levered Free Cash Flow | -0.01 | -36.34 | -17.07 | -12.82 | 10.88 | Upgrade
|
| Unlevered Free Cash Flow | 8.65 | -30.19 | -10.4 | -7.98 | 11.42 | Upgrade
|
| Change in Working Capital | 3.23 | -34.38 | 17.46 | 4.91 | -12.91 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.